DOCSLIB.ORG

Cells by OX40 Ligand and CD70 on Activated B CD28-Independent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cells by OX40 Ligand and CD70 on Activated B CD28-Independent CD28-Independent Costimulation of T Cells by OX40 Ligand and CD70 on Activated B Cells1 Hisaya Akiba,*† Hideo Oshima,*‡ Kazuyoshi Takeda,*† Machiko Atsuta,*† Hiroyasu Nakano,*† Atsuo Nakajima,§ Chiyoko Nohara,* Hideo Yagita,*† and Ko Okumura2*† OX40 and its ligand (OX40L) have been implicated in T cell-dependent humoral immune responses. To further characterize the role of OX40/OX40L in T-B cell interaction, we newly generated an anti-mouse OX40L mAb (RM134L) that can inhibit the costimulatory activity of OX40L transfectants for anti-CD3-stimulated T cell proliferation. Flow cytometric analyses using RM134L and an anti-mouse OX40 mAb indicated that OX40 was inducible on splenic T cells by stimulation with immobilized anti-CD3 mAb in a CD28-independent manner, while OX40L was not expressed on resting or activated T cells. OX40L was inducible on splenic B cells by stimulation with anti-IgM Ab plus anti-CD40 mAb, but not by either alone. These activated B cells exhibited a potent costimulatory activity for anti-CD3-stimulated T cell proliferation and IL-2 production. Anti-CD80 and anti- CD86 mAbs partially inhibited the costimulatory activity, and further inhibition was obtained by their combination with RM134L and/or anti-CD70 mAb. We also found the anti-IgM Ab- plus anti-CD40 mAb-stimulated B cells exhibited a potent costimulatory activity for proliferation of and IL-2 production by anti-CD3-stimulated CD282 T cells from CD28-deficient mice, which was substantially inhibited by RM134L and/or anti-CD70 mAb. These results indicated that OX40L and CD70 expressed on surface Ig- and CD40-stimulated B cells can provide CD28-independent costimulatory signals to T cells. The Journal of Immunology, 1999, 162: 7058–7066. n humoral immune responses, the cognate interaction be- superfamily, can provide a costimulatory signal to T cells, result- tween Ag-specific T cells and B cells is critical not only for ing in increased proliferation and cytokine production (10–12). B cell activation but also for T cell activation. Optimal acti- OX40 was originally identified as a cell surface Ag on activated I 1 vation of Ag-specific T cells requires engagement of the TCR with CD4 T cells in rats (13). cDNA cloning of rat, mouse, and human Ag/MHC and a costimulatory signal provided by APC (1, 2). It has OX40 showed that it belongs to the TNF receptor superfamily been shown that CD28 on T cells and its ligands (CD80 and CD86) (14–16). It has been reported that expression of OX40 is restricted on APC play a major role in providing a costimulatory signal for to activated T cells in rats, humans, and mice (13, 15, 17). On the T cells (3–5). However, CD28-deficient mice are not fully defec- other hand, expression of OX40L has been found on mouse acti- by guest on October 1, 2021. Copyright 1999 Pageant Media Ltd. tive in humoral immune responses (6, 7). It has also been demon- vated B cells (15, 18), human dendritic cells (DC) (19), human strated that activated B cells exhibited a potent costimulatory ac- vascular endothelial cells (20), and human and rat HTLV-1-trans- 1 tivity for proliferation of CD4 T cells from CD28-deficient mice formed T cells (10, 21). Recent studies demonstrated that ligation (8). These results suggested the existence of a CD28-independent of OX40L on human DC enhanced their maturation and produc- costimulatory pathway. tion of cytokines (19) and that blockade of OX40L during naive We previously demonstrated that CD27, which is a member of T-DC interaction suppressed the development of IL-4-producing T the TNF receptor superfamily and is constitutively expressed on cells (22), suggesting that OX40-OX40L may play an important most T cells, can transmit a CD28-independent costimulatory sig- role in T-DC interaction. In addition, OX40L expressed on acti- nal upon interaction with its ligand CD70 expressed on a mouse B http://classic.jimmunol.org vated B cells has been shown to transmit a signal that enhances the lymphoma cell line (9). In addition, we and others have shown that proliferation of and Ig secretion by B cells (18). This suggested OX40 ligand (OX40L),3 which is another member of the TNF that the cross-linking of OX40L on B cells by OX40 on T cells might deliver a B cell differentiation signal, and thus, the OX40- OX40L system might play a unique role in T-B interaction. To *Department of Immunology, Juntendo University School of Medicine, Tokyo, Ja- support this idea, it has been reported that administration of an pan; †CREST (Core Research for Evolutional Science and Technology) of Japan ‡ anti-OX40 Ab inhibited the T cell-dependent humoral immune Downloaded from Science and Technology Corporation, Tokyo, Japan; Department of Surgery, Faculty of Medicine, University of Tokyo, Tokyo, Japan; and §Department of Joint Disease response in mice, possibly by interrupting the OX40-OX40L and Rheumatism, Nippon Medical School, Tokyo, Japan interaction (23). Received for publication February 9, 1999. Accepted for publication March 31, 1999. To further characterize the role of OX40/OX40L in T-B cell The costs of publication of this article were defrayed in part by the payment of page interaction, we established a functional blocking mAb against charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. mouse OX40L, which will be useful for interrupting the OX40- 1 This work was supported in part by grants from the Science and Technology Agen- OX40L interaction in vivo. Our present study formally defined the cy; the Ministry of Education, Science, and Culture; and the Ministry of Health, expression of OX40 and OX40L on activated T and B cells. We Japan. found that the expression of OX40 on activated T cells is CD28 2 Address correspondence and reprint requests to Dr. Ko Okumura, Department of independent, and the CD28-independent costimulatory activity of Immunology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. E-mail address: [email protected] surface Ig- and CD40-activated B cells is coordinately mediated by 3 Abbreviations used in this paper: OX40L, OX40 ligand; DC, dendritic cells; OX40L and CD70. The physiological relevance of these findings HTLV-1, human T cell leukemia virus type I; CD40L, CD40 ligand. is discussed. Copyright © 1999 by The American Association of Immunologists 0022-1767/99/$02.00 The Journal of Immunology 7059 Materials and Methods 123–142 of murine OX40L cDNA (11) tagged with an XhoI site and 59- 9 Animals and cell lines GACGCGGCCGCGTCCACCCTCAGAGTGGAA-3 corresponding to nucleotides 721–739 tagged with a NotI site were used as 59 and 39 primers, Six- to seven-week-old male DBA/2 and C57BL/6 mice and 6-wk-old respectively. The PCR product was cloned into pMKITneo vector, pro- female SD rats were purchased from Charles River Japan (Atsugi, Japan). vided by Dr. K. Maruyama (Tokyo Medical and Dental University, Tokyo, Six- to seven-week-old C57BL/6 CD28-deficient (2/2) mice were pur- Japan), and transfected into L5178Y, NRK-52E, and P815 cells by elec- chased from The Jackson Laboratory (Bar Harbor, ME). Murine mastcy- troporation. Mock-transfected cells were also produced by electroporation toma P815, murine T lymphoma L5178Y, murine B lymphomas A20.2J of the pMKITneo vector without an insert. After selection by 1 mg/ml of and 2PK-3, and murine myeloma P3U1 (P3 x 63Ag8U.1) were purchased geneticin, transfectants stably expressing OX40L were identified by stain- from American Type Culture Collection (Manassas, VA). The hybridomas ing with OX40-Ig. producing mAbs against MHC class II (M5/114), heat stable Ag (J11d), B220 (RA3-3A1), CD8 (3.155), and Thy1.2 (J1j) were also obtained from Generation of anti-mouse OX40L mAb American Type Culture Collection. The hybridoma OX86 producing anti- An SD rat was immunized with OX40L-transfected NRK cells three times mouse OX40 mAb (24) was obtained from European Collection of Cell at 7-day intervals. Three days after final immunization, the splenocytes Cultures (Wiltshire, U.K.). The hybridoma producing mAb against CD4 were fused with P3U1 cells as previously described (31). After hypoxan- (RL172) was provided by Dr. T. Tanaka (Tokyo Metropolitan Institute of thine-aminopterin-thymidine selection, one hybridoma producing mAb Medical Science, Tokyo, Japan). A murine B lymphoma cell line BCL1- RM134L (rat IgG2b, k) was identified by its strong reactivity with OX40L- B20 (25) was provided by Dr. K. Takatsu (Institute of Medical Science, transfected L5178Y cells, but not with mock-transfected L5178Y cells, and University of Tokyo, Tokyo, Japan). A murine T lymphoma cell line was cloned by limiting dilution. RM134L was purified from ascites by MBL2 (26) was provided by Dr. T. Nishimura (Tokai University, Kana- standard procedures with caprylic acid, and purity was verified by SDS- gawa, Japan). These cells were cultured in RPMI 1640 medium contain- PAGE analysis. ing 10% FCS, 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyru- vate, 0.1 mg/ml penicillin and streptomycin, and 50 mM 2-ME. Preparation and culture of splenic T cells and B cells A normal rat kidney cell line, NRK-52E (27), was provided by Dr. T. Otsuka (Institute of Cytosignal Research, Tokyo, Japan) and was Splenic T and B cells were purified as previously described (9). Briefly, cultured in DMEM containing 10% FCS, 10 mM HEPES, 4 mM L-glu- splenic T cells were purified by passage through nylon wool column tamine, 1 mM sodium pyruvate, 0.1 mg/ml penicillin and streptomycin, (Wako, Osaka, Japan) and treatment with a mixture of hybridoma super- and 50 mM 2-ME.
Load more

Recommended publications
  • Critical Contribution of OX40 Ligand to T Helper Cell Type 2
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Brief Definitive Report Critical Contribution of OX40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis By Hisaya Akiba,*§ Yasushi Miyahira,‡ Machiko Atsuta,*§ Kazuyoshi Takeda,*§ Chiyoko Nohara,* Toshiro Futagawa,* Hironori Matsuda,* Takashi Aoki,‡ Hideo Yagita,*§ and Ko Okumura*§ From the *Department of Immunology and the ‡Department of Parasitology, Juntendo University School of Medicine, Tokyo 113-8421, Japan; and §CREST (Core Research for Evolutional Science and Technology) of Japan Science and Technology Corporation, Tokyo 101-0062, Japan Abstract Infection of inbred mouse strains with Leishmania major is a well characterized model for analy- sis of T helper (Th)1 and Th2 cell development in vivo. In this study, to address the role of co- stimulatory molecules CD27, CD30, 4-1BB, and OX40, which belong to the tumor necrosis factor receptor superfamily, in the development of Th1 and Th2 cells in vivo, we administered monoclonal antibody (mAb) against their ligands, CD70, CD30 ligand (L), 4-1BBL, and OX40L, to mice infected with L. major. Whereas anti-CD70, anti-CD30L, and anti–4-1BBL mAb ex- hibited no effect in either susceptible BALB/c or resistant C57BL/6 mice, the administration of anti-OX40L mAb abrogated progressive disease in BALB/c mice. Flow cytometric analysis indicated that OX40 was expressed on CD41 T cells and OX40L was expressed on CD11c1 dendritic cells in the popliteal lymph nodes of L. major–infected BALB/c mice. In vitro stimu- lation of these CD41 T cells showed that anti-OX40L mAb treatment resulted in substantially reduced production of Th2 cytokines.
    [Show full text]
  • A Fratricide-Resistant Allogeneic CAR T
    Investigation of ALLO-316: A Fratricide- Resistant Allogeneic CAR T Targeting CD70 As a Potential Therapy for the Treatment of AML Surabhi Srinivasan, Nguyen Tan, Hsin-Yuan Cheng, Yi Zhang, Silvia Tacheva-Grigorova, Tom Van Blarcom, Cesar Sommer, Duy Nguyen , Barbra Sasu, and Siler Panowski 1 Disclosures • Full-time employee of Allogene Therapeutics • Equity interest in Allogene Therapeutics ALLO-316 (CD70) utilizes TALEN® gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at this target and holds all global development and commercial rights for this investigational candidate. 22 CONFIDENTIAL Disclaimers This presentation is not intended for product promotion. All information is related to investigational therapies not available for commercial use. The safety and efficacy of the therapies have not been established for FDA approval. Forward-Looking Statements To the extent statements contained in this Presentation are not descriptions of historical facts regarding Allogene Therapeutics, Inc. (“Allogene,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this Presentation include, but are not limited to, statements regarding: the ability to progress the clinical development of allogeneic CAR T (AlloCAR T™) therapies and the potential benefits of AlloCAR T™ therapy, including ALLO-316.
    [Show full text]
  • Uva-DARE (Digital Academic Repository)
    UvA-DARE (Digital Academic Repository) Balancing effector lymphocyte formation via CD27-CD70 interactions Arens, R. Publication date 2003 Link to publication Citation for published version (APA): Arens, R. (2003). Balancing effector lymphocyte formation via CD27-CD70 interactions. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:27 Sep 2021 Chapter 3 Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNy-mediated B cell depletion Ramon Arens*, Kiki Tesselaar*, Paul A. Baars, Gijs M.W. van Schijndel, Jenny Hendriks, Steven T. Pals, Paul Krimpenfort, Jannie Borst, Marinus H.J. van Oers, and René A.W. van Lier 'These authors contributed equally to this work Immunity 15, 801-812 (2001) Chapter 3 Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNy-mediated B cell depletion Ramon Arens123#, Kiki Tesselaar23", Paul A.
    [Show full text]
  • Belongs to the TNF Family a New Class of Reverse Signaling
    A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink This information is current as J Immunol 2007; 179:4307-4312; ; of September 27, 2021. doi: 10.4049/jimmunol.179.7.4307 http://www.jimmunol.org/content/179/7/4307 References This article cites 85 articles, 38 of which you can access for free at: Downloaded from http://www.jimmunol.org/content/179/7/4307.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision http://www.jimmunol.org/ • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: by guest on September 27, 2021 http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2007 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY BRIEF REVIEWS A New Class of Reverse Signaling Costimulators Belongs to the TNF Family Mingyi Sun and Pamela J. Fink1 Recent evidence shows that many molecules of the TNF still remains unclear (7). The N-terminal cytoplasmic domains family serve as counter-receptors, inducing costimulation of most TNF family members are conserved across species but through reverse signals in addition to delivering signals not between family members, suggesting that the intracellular through their respective TNF receptors.
    [Show full text]
  • Co-Expression of CD40L with CD70 Or OX40L Increases B-Cell Viability and Antitumor Efficacy
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 29 Research Paper Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy Chang-Ae Shin1, Hyun-Woo Cho1, A-Ri Shin2,3, Hyun-Jung Sohn2, Hyun-Il Cho2,3, Tai-Gyu Kim1,2,3 1Department of Microbiology and Immunology, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea 2Catholic Hematopoietic Stem Cell Bank, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea 3Catholic Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 137-701, South Korea Correspondence to: Hyun-Il Cho, email: [email protected] Tai-Gyu Kim, email: [email protected] Keywords: cancer vaccine, B-cells, costimulatory ligand, anti-apoptosis, tumor immunity Received: February 24, 2016 Accepted: May 29, 2016 Published: June 15, 2016 ABSTRACT Activated B-cells are a promising alternative source of antigen-presenting cells. They can generally be obtained in sufficient numbers for clinical use, but in most instances produce weak immune responses and therapeutic effects that are suboptimal for use in therapeutic cancer vaccines. To improve the immunogenic potency and therapeutic efficacy of B-cell-based vaccines, ex vivo-activated B-cells were transduced with recombinant lentiviruses in order to express additional costimulatory ligands—CD40L, CD70, OX40L, or 4-1BBL—either individually or in pairs (CD70/CD40L, OX40L/CD40L, or 4-1BBL/CD40L). We observed that the expression of CD40L molecules on B-cells was crucial for T-cell priming and activation. Administration of B-cells co-expressing CD40L with the other costimulatory ligands provided substantial antigen-specific CD8 T-cell responses capable of provoking in vivo proliferation and potent cytolytic activities.
    [Show full text]
  • CD70 Knockout: a Novel Approach to Augment CAR-T Cell Function
    #1537 CD70 knockout: A novel approach to augment CAR-T cell function Mary-Lee Dequeant, Jason Sagert, Demetri Kalaitzidis, Hui Yu, Ashley Porras, Brigid McEwan, Zinkal Padalia, Paul Tetteh, Thao Nguyen, Andrew Dunn, Sarah Spencer, Nicolette Lee, Henia Dar, Daniel Henderson, Sushant Karnik, Pooja Keerthipati, Jonathan A. Terrett CRISPR Therapeutics, 610 Main Street, Cambridge, MA, USA 02139 Abstract KO of certain checkpoint genes is detrimental to CAR-T function CD70 and its ligand, CD27, have been described as both activating and suppressing for different cell types including B and T cells. There has been speculation that the CD70/CD27 axis can act in a checkpoint or co-stimulatory manner in certain Figure 8: CD70 KO confers superior cytotoxic activity than PD1 KO against an RCC Figure 10: KO of multiple checkpoint genes impairs CAR-T cell function immuno-oncology settings. Knockout (KO) of CD70 function scored highly in a CRISPR/Cas9 screen of candidate genes for enhanced T cell activity. Deletion of other checkpoint candidates such as PD1, TIM3, LAG3 and TIGIT scored much lower than CD70, both alone and in combination with each other. T cells with CD70 KO showed resistance to exhaustion upon repeated stimulation in culture. CAR-T cells with CD70 KO similarly showed exhaustion resistance, as well as a reduction in tumor cell line overexpressing PD-L1 A Input Bone Marrow (Day 100) 10000 apoptosis, increased proliferation, and improved target cell lysis upon sequential rechallenges. CTX130 is an investigational allogeneic CAR-T therapy currently being studied in patients with CD70-expressing tumors, including clear cell renal cell 100 2500 No RNP or AAV carcinoma and B and T cell malignancies.
    [Show full text]
  • Immunity in the Developing Lung Foxa2 Programs Th2 Cell-Mediated
    Foxa2 Programs Th2 Cell-Mediated Innate Immunity in the Developing Lung Gang Chen, Huajing Wan, Fengming Luo, Liqian Zhang, Yan Xu, Ian Lewkowich, Marsha Wills-Karp and Jeffrey A. This information is current as Whitsett of September 27, 2021. J Immunol 2010; 184:6133-6141; Prepublished online 5 May 2010; doi: 10.4049/jimmunol.1000223 http://www.jimmunol.org/content/184/11/6133 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2010/05/05/jimmunol.100022 Material 3.DC1 http://www.jimmunol.org/ References This article cites 59 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/184/11/6133.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 27, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Foxa2 Programs Th2 Cell-Mediated Innate Immunity in the Developing Lung Gang Chen,* Huajing Wan,† Fengming Luo,‡ Liqian Zhang,* Yan Xu,* Ian Lewkowich,x Marsha Wills-Karp,x and Jeffrey A.
    [Show full text]
  • CD154-Independent Rejection Critical Role of OX40 in CD28
    Critical Role of OX40 in CD28 and CD154-Independent Rejection Gülçin Demirci, Farhana Amanullah, Reshma Kewalaramani, Hideo Yagita, Terry B. Strom, Mohamed H. This information is current as Sayegh and Xian Chang Li of October 1, 2021. J Immunol 2004; 172:1691-1698; ; doi: 10.4049/jimmunol.172.3.1691 http://www.jimmunol.org/content/172/3/1691 Downloaded from References This article cites 42 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/172/3/1691.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on October 1, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Critical Role of OX40 in CD28 and CD154-Independent Rejection1 Gu¨lc¸in Demirci,* Farhana Amanullah,* Reshma Kewalaramani,† Hideo Yagita,‡ Terry B. Strom,* Mohamed H. Sayegh,† and Xian Chang Li*2 Blocking both CD28 and CD154 costimulatory pathways can induce transplant tolerance in some, but not all, transplant models.
    [Show full text]
  • CD70 CD27 Ligation Between Neural Stem Cells and CD4+ T Cells
    Lee et al. Stem Cell Research & Therapy 2013, 4:56 http://stemcellres.com/content/4/3/56 RESEARCH Open Access CD70–CD27 ligation between neural stem cells and CD4+ T cells induces Fas–FasL-mediated T-cell death Eun Mi Lee1,2, Sunghoon Hurh1, Bumrae Cho1, Kook-Hwan Oh3, Seung U Kim4, Charles D Surh5, Jonathan Sprent6, Jaeseok Yang7, Jae Young Kim8 and Curie Ahn1,3,7* Abstract Introduction: Neural stem cells (NSCs) are among the most promising candidates for cell replacement therapy in neuronal injury and neurodegenerative diseases. One of the remaining obstacles for NSC therapy is to overcome the alloimmune response on NSCs by the host. Methods: To investigate the mechanisms of immune modulatory function derived from the interaction of human NSCs with allogeneic T cells, we examined the immune regulatory effects of human NSCs on allogeneic T cells in vitro. Results: Significantly, NSCs induced apoptosis of allogeneic T cells, in particular CD4+ T cells. Interaction of CD70 on NSCs and CD27 on CD4+ T cells mediated apoptosis of T cells. Thus, blocking CD70–CD27 interaction prevented NSC-mediated death of CD4+ T cells. Conclusions: We present a rational explanation of NSC-induced immune escape in two consecutive stages. First, CD70 constitutively expressed on NSCs engaged CD27 on CD4+ T cells, which induced Fas ligand expression on CD4+ T cells. Second, CD4+ T-cell apoptosis was followed by Fas–Fas ligand interaction in the CD4+ T cells. Keywords: Neural stem cells, Co-stimulatory molecules, Immune escape mechanism Introduction Transplantation of rodent embryonic stem cells (ESCs) Neural stem cells (NSCs) are among the most promising into allogeneic recipients indicated that they may have candidates for cell replacement therapy in neuronal in- immune-privileged properties.
    [Show full text]
  • Lnvited Review Memory B Cells and CD27
    HistolHistopathol (2000) 15: 573-576 Histology and 001 : 10.14670/HH-15.573 H istopathology http://www.hh .um.es Gel/u/ar and Molecular Biology lnvited Review Memory B cells and CD27 K. Agematsu Departmentcf Pediatrics,ShinshuUniversity School cf Medicine,Matsumoto,Japan Summary. Following antigen activation in germinal expressed on the surface, immature B cells become centers, B cells develop into memory B cells or plasma mature B cells. The mature B cells become activated in cells. Triggering vía B-cell immunoglobulin receptors by the T cell zones of PALS and then migrate into B cell antigens, cytokines and direct cell-to-cell contact by B zones to form germinal centers. and T cells plays an important role in the B cell To produce antibodies, the differentiation of B cells differentiation into memory or plasma cells. Adult into specific antibody-secreting cells (plasma cells) is human peripheral blood B cells are separated into three required. Triggering vía B cell immunoglobulin subtypes by the expression of lgD and CD27, which receptors by antigens, cytokines such as IL-2, IL-6 and belong to the tumor necrosis factor receptor (TNFR) IL-10, and direct cell-to-cell contact between T and B family: IgD+ CD27- naive B cells, IgD+ CD27+ and cells plays an important role in the differentiation of IgD- CD27+ B cells. CD27+ B cells are larger cells with mature B cells. However, the mechanism of abundant cytoplasm carrying somatic hypermutation, differentiation toward memory B cells or plasma cells and have an ability to produce immunoglobulin, from mature B cells has been unclear until now.
    [Show full text]
  • Memory B Cells Into Plasma Cells Secretion by Promoting The
    CD27/CD70 Interaction Augments IgE Secretion by Promoting the Differentiation of Memory B Cells into Plasma Cells This information is current as Haruo Nagumo, Kazunaga Agematsu, Koji Shinozaki, Sho of October 2, 2021. Hokibara, Susumu Ito, Masaya Takamoto, Toshio Nikaido, Kozo Yasui, Yoshio Uehara, Akihiro Yachie and Atsushi Komiyama J Immunol 1998; 161:6496-6502; ; http://www.jimmunol.org/content/161/12/6496 Downloaded from References This article cites 41 articles, 32 of which you can access for free at: http://www.jimmunol.org/content/161/12/6496.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 1998 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. CD27/CD70 Interaction Augments IgE Secretion by Promoting the Differentiation of Memory B Cells into Plasma Cells Haruo Nagumo,* Kazunaga Agematsu,1* Koji Shinozaki,* Sho Hokibara,* Susumu Ito,† Masaya Takamoto,‡ Toshio Nikaido,§ Kozo Yasui,* Yoshio Uehara,¶ Akihiro Yachie,i and Atsushi Komiyama* The induction of IgE switching in B cells requires several signals given by cytokines and cell contact-delivered signals.
    [Show full text]
  • Characterisation of Chicken OX40 and OX40L
    Characterisation of chicken OX40 and OX40L von Stephanie Hanna Katharina Scherer Inaugural-Dissertation zur Erlangung der Doktorw¨urde der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Characterisation of chicken OX40 and OX40L von Stephanie Hanna Katharina Scherer aus Baunach bei Bamberg M¨unchen2018 Aus dem Veterin¨arwissenschaftlichenDepartment der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Lehrstuhl f¨urPhysiologie Arbeit angefertigt unter der Leitung von Univ.-Prof. Dr. Thomas G¨obel Gedruckt mit Genehmigung der Tier¨arztlichenFakult¨at der Ludwig-Maximilians-Universit¨atM¨unchen Dekan: Univ.-Prof. Dr. Reinhard K. Straubinger, Ph.D. Berichterstatter: Univ.-Prof. Dr. Thomas G¨obel Korreferenten: Priv.-Doz. Dr. Nadja Herbach Univ.-Prof. Dr. Bernhard Aigner Prof. Dr. Herbert Kaltner Univ.-Prof. Dr. R¨udiger Wanke Tag der Promotion: 27. Juli 2018 Meinen Eltern und Großeltern Contents List of Figures 11 Abbreviations 13 1 Introduction 17 2 Fundamentals 19 2.1 T cell activation . 19 2.1.1 The activation of T cells requires the presence of several signals 19 2.1.2 Costimulatory signals transmitted via members of the im- munoglobulin superfamily . 22 2.1.3 Costimulatory signals transmitted via members of the cy- tokine receptor family . 23 2.1.4 Costimulatory signals transmitted via members of the tumour necrosis factor receptor superfamily . 24 2.2 The tumour necrosis factor receptor superfamily . 26 2.2.1 The structure of tumour necrosis factor receptors . 26 2.2.2 Functional classification of TNFRSF members . 28 2.3 The tumour necrosis factor superfamily . 29 2.3.1 The structure of tumour necrosis factor ligands .
    [Show full text]